Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icanbelimod in Moderate to Severe Ulcerative Colitis
NCT04700449Phase 2Completed
- Sponsor
- Connect Biopharma
- Start
- Feb 2019
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of icanbelimod in ulcerative colitis (UC), sponsored by Connect Biopharma. Primary endpoint: Change From Baseline for Adapted Mayo Score at 48 weeks. Started Feb 2019; status: completed.
02
Drugs
icanbelimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04700449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04700449.